Lazard Asset Management’s Esperion Therapeutics ESPR Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.59M	Buy	580,705 +546,964	+1,621%	+$1.73M	﹤0.01%	1012
2025 Q4	$125K	Buy	+33,741	New	+$109K	﹤0.01%	1721
2025 Q2	–	Sell	-43,815	Closed	-$63K	–	2363
2025 Q1	$63K	Buy	43,815 +31,464	+255%	+$58K	﹤0.01%	1942
2024 Q4	$27K	Hold	12,351	–	–	﹤0.01%	2050
2024 Q3	$20K	Buy	12,351 +657	+6%	+$1.33K	﹤0.01%	1999
2024 Q2	$25K	Buy	+11,694	New	+$27.5K	﹤0.01%	2004
2023 Q1	–	Sell	-145,953	Closed	-$909K	–	2375
2022 Q4	$909K	Buy	145,953 +62,385	+75%	+$446K	﹤0.01%	1014
2022 Q3	$559K	Buy	83,568 +51,176	+158%	+$351K	﹤0.01%	1080
2022 Q2	$206K	Sell	32,392 -24,035	-43%	-$136K	﹤0.01%	1276
2022 Q1	$261K	Buy	56,427 +20,136	+55%	+$86.4K	﹤0.01%	1211
2021 Q4	$181K	Sell	36,291 -133,109	-79%	-$1.07M	﹤0.01%	1297
2021 Q3	$2.04M	Buy	169,400 +142,400	+527%	+$2.07M	﹤0.01%	911
2021 Q2	$571K	Buy	+27,000	New	+$650K	﹤0.01%	1039
2018 Q2	–	Sell	-12,106	Closed	-$875K	–	1053
2018 Q1	$875K	Buy	+12,106	New	+$889K	﹤0.01%	725
2015 Q3	–	Sell	-1,450	Closed	-$118K	–	1099
2015 Q2	$118K	Sell	1,450 -24,795	-94%	-$2.43M	﹤0.01%	897
2015 Q1	$2.43M	Buy	26,245 +26,045	+13,023%	+$1.68M	0.01%	617
2014 Q4	$8K	Buy	+200	New	+$6.12K	﹤0.01%	1089